Charles V. Baltic Iii JD

Charles Baltic joined Needham & Company in March 2009. Charles is the Co-Head of the Investment Banking Healthcare Group. He has over 20 years of experience working with life sciences and healthcare companies in a significant variety of transactional contexts. Prior to joining Needham, Charles was a Managing Director and Head of the Biotechnology Investment Banking practice at CRT Capital Group from 2006 to 2009. From 2001 to 2006, he served as a Managing Director in Healthcare Investment Banking at Wachovia Securities (now Wells Fargo Securities) where he founded Wachovia’s Biotechnology Investment Banking practice. Prior to Wachovia, he was with Healthcare Investment Banking at Cowen and Company from 1996 - 2001. Prior to 1996, Charles practiced corporate and securities law with Dewey Ballantine. He serves on the Board of Directors of MEI Pharma (NASDAQ: MEIP), an oncology-focused biopharmaceutical company, and SIDIS, Inc., a life sciences investment holding company. He is also a member of the U.S. Securities and Exchange Commission's Advisory Committee on Small and Emerging Companies. Charles is a founding Trustee of the Hope Funds for Cancer Research, a Trustee of the Washington Biotechnology and Biomedical Association (WBBA), and a former Director of Med-Vantage Inc., a health informatics company which was acquired by IMS Health in 2011. He holds B.A. and J.D. degrees from Georgetown University and a MBA degree in finance from the Wharton School of the University of Pennsylvania.